186 related articles for article (PubMed ID: 36987723)
21. Higher infused lymphocyte dose predicts higher lymphocyte recovery, which in turn, predicts superior overall survival following autologous hematopoietic stem cell transplantation for multiple myeloma.
Hiwase DK; Hiwase S; Bailey M; Bollard G; Schwarer AP
Biol Blood Marrow Transplant; 2008 Jan; 14(1):116-24. PubMed ID: 18158968
[TBL] [Abstract][Full Text] [Related]
22. [Clinical Analysis of 46 Cases of Multiple Myeloma with Extramedullary Disease].
Chao Y; Fan L; Gao XY; Ma YP
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2021 Feb; 29(1):115-121. PubMed ID: 33554807
[TBL] [Abstract][Full Text] [Related]
23. [Clinical characteristics and prognosis of patients with newly-diagnosed multiple myeloma with t(11;14)].
Wang Y; Liu YF; Tao Y; Jin SW; Mi JQ
Zhonghua Yi Xue Za Zhi; 2022 Sep; 102(36):2868-2873. PubMed ID: 36153872
[No Abstract] [Full Text] [Related]
24. Daratumumab, pomalidomide, and dexamethasone (DPd) followed by high dose chemotherapy-Autologous Stem Cell Transplantation leads to superior outcomes when compared to DPd-alone for patients with Relapsed Refractory Multiple Myeloma.
Hashmi H; Atrash S; Jain J; Khasawneh G; Mohan M; Mahmoudjafari Z; Cui W; McGuirk J; Shune L; Ahmed N; Abdallah AO
Transplant Cell Ther; 2023 Apr; 29(4):262.e1-262.e6. PubMed ID: 36682468
[TBL] [Abstract][Full Text] [Related]
25. Retrospective analysis of the efficacy and influencing factors of autologous hematopoietic stem cell transplantation for multiple myeloma.
Zhang BL; Zhou J; Lin QD; Liu YZ; Zhang YL; Gui RR; Song YP; Fang BJ
Artif Organs; 2019 Oct; 43(10):1028-1034. PubMed ID: 30972806
[TBL] [Abstract][Full Text] [Related]
26. 1q21+ is associated with poor prognosis in newly diagnosed multiple myeloma patients with extramedullary disease: a retrospective study.
Gao S; Dong F; Yang P; Chen Y; Wang Y; Wang J; Shi Y; Jing H
Ann Hematol; 2024 Jun; 103(6):1979-1987. PubMed ID: 38206369
[TBL] [Abstract][Full Text] [Related]
27. [Prognostic Value of CD56 Expression in Newly Diagnosed Multiple Myeloma Patients and Its Related Factors].
Wang XX; Zhang LL; Wang T; Hou JX; Wang ZT; Qin H
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2023 Jun; 31(3):777-782. PubMed ID: 37356939
[TBL] [Abstract][Full Text] [Related]
28. Prognostic Implications of Rising Serum Monoclonal Protein and Free Light Chains after Autologous Stem Cell Transplantation in Patients with Multiple Myeloma.
Parmar H; Al Saleh AS; Visram A; Warsame R; Kourelis T; Gonsalves W; Dingli D; Muchtar E; Hayman S; Kapoor P; Buadi F; Dispenzieri A; Lacy M; Gertz M; Kumar S
Transplant Cell Ther; 2021 Apr; 27(4):309.e1-309.e5. PubMed ID: 33836869
[TBL] [Abstract][Full Text] [Related]
29. Prognostic Role of Beta-2 Microglobulin in Patients with Light Chain Amyloidosis Treated with Autologous Stem Cell Transplantation.
Al Saleh AS; Sidiqi MH; Muchtar E; Buadi FK; Dispenzieri A; Warsame R; Lacy MQ; Dingli D; Gonsalves WI; Kourelis TV; Hogan WJ; Hayman SR; Kapoor P; Kumar SK; Gertz MA
Biol Blood Marrow Transplant; 2020 Aug; 26(8):1402-1405. PubMed ID: 32422250
[TBL] [Abstract][Full Text] [Related]
30. [Analysis of the clinical characteristics and prognosis of 36 cases of newly diagnosed multiple myeloma patients with bone marrow monoclonal plasma cell ratio of less than 10].
Zhao JT; Jiang XY; Yang C; Chen M; Lan XL; Du JH; Zhou DB; Zhuang JL
Zhonghua Xue Ye Xue Za Zhi; 2021 Apr; 42(4):295-301. PubMed ID: 33979973
[No Abstract] [Full Text] [Related]
31. [Bortezomib-based induction therapy followed by autologous hematopoietic stem cell transplantation in multiple myeloma].
Huang B; Li J; Liu J; Gu J; Zheng D; Xu D; Zou W; Wang H
Zhonghua Nei Ke Za Zhi; 2014 Nov; 53(11):865-72. PubMed ID: 25586356
[TBL] [Abstract][Full Text] [Related]
32. Multiple Extramedullary-Bone Related and/or Extramedullary Extraosseous Are Independent Poor Prognostic Factors in Patients With Newly Diagnosed Multiple Myeloma.
He J; Yue X; He D; Zhao Y; Yang Y; Zheng G; Zhang E; Han X; Wu W; Yang L; Chen J; Cai Z
Front Oncol; 2021; 11():668099. PubMed ID: 34307138
[TBL] [Abstract][Full Text] [Related]
33. The role of positron emission tomography with 18F-fluorodeoxyglucose integrated with computed tomography in the evaluation of patients with multiple myeloma undergoing allogeneic stem cell transplantation.
Patriarca F; Carobolante F; Zamagni E; Montefusco V; Bruno B; Englaro E; Nanni C; Geatti O; Isola M; Sperotto A; Buttignol S; Stocchi R; Corradini P; Cavo M; Fanin R
Biol Blood Marrow Transplant; 2015 Jun; 21(6):1068-73. PubMed ID: 25754658
[TBL] [Abstract][Full Text] [Related]
34. Comparison of clinical characteristics, treatment efficacy and survival in patients with newly diagnosed multiple myeloma with single- versus multi-site extramedullary invasion.
Zhao Y; Zhou F
J Cancer Res Clin Oncol; 2023 Mar; 149(3):995-1006. PubMed ID: 35212816
[TBL] [Abstract][Full Text] [Related]
35. Prognostic value of low muscle mass at the 12
Park SS; Kwag D; Lee JY; Jeon YW; Yahng SA; Shin SH; Youn SY; Min CK
Diagn Interv Radiol; 2023 Jul; 29(4):596-608. PubMed ID: 37312491
[TBL] [Abstract][Full Text] [Related]
36. Benefits of Autologous Stem Cell Transplantation for Elderly Myeloma Patients in the Last Quarter of Life.
Joseph NS; Gupta VA; Wyman S; Graiser M; Kaufman JL; Almaula D; Andrews J; Hofmeister C; Dhodapkar M; Heffner LT; Lonial S; Nooka AK
Transplant Cell Ther; 2022 Feb; 28(2):75.e1-75.e7. PubMed ID: 34626863
[TBL] [Abstract][Full Text] [Related]
37. [Influence of the number of high-risk cytogenetic abnormalities on the clinical characteristics and prognosis in 360 patients with newly diagnosed multiple myeloma].
Chen Z; Xia Y; Guo R; Zhang R; Qiu HR; Jin YY; Li JY; Chen LJ
Zhonghua Xue Ye Xue Za Zhi; 2022 May; 43(5):408-413. PubMed ID: 35680599
[No Abstract] [Full Text] [Related]
38. Prognostic relevance of 18-F FDG PET/CT in newly diagnosed multiple myeloma patients treated with up-front autologous transplantation.
Zamagni E; Patriarca F; Nanni C; Zannetti B; Englaro E; Pezzi A; Tacchetti P; Buttignol S; Perrone G; Brioli A; Pantani L; Terragna C; Carobolante F; Baccarani M; Fanin R; Fanti S; Cavo M
Blood; 2011 Dec; 118(23):5989-95. PubMed ID: 21900189
[TBL] [Abstract][Full Text] [Related]
39. Tandem Autologous Stem Cell Transplantation Improves Outcomes in Newly Diagnosed Multiple Myeloma with Extramedullary Disease and High-Risk Cytogenetics: A Study from the Chronic Malignancies Working Party of the European Society for Blood and Marrow Transplantation.
Gagelmann N; Eikema DJ; Koster L; Caillot D; Pioltelli P; Lleonart JB; Reményi P; Blaise D; Schaap N; Trneny M; Passweg J; Porras RP; Cahn JY; Musso M; Poiré X; Fenk R; Itälä-Remes M; Pavone V; Fouillard L; Maertens J; Bron D; Pouli A; Schroyens W; Schönland S; Garderet L; Yakoub-Agha I; Kröger N
Biol Blood Marrow Transplant; 2019 Nov; 25(11):2134-2142. PubMed ID: 31288095
[TBL] [Abstract][Full Text] [Related]
40. Impact of Extraosseous Extramedullary Disease on Outcomes of Patients with Relapsed-Refractory Multiple Myeloma receiving Standard-of-Care Chimeric Antigen Receptor T-Cell Therapy.
Dima D; Abdallah AO; Davis JA; Awada H; Goel U; Rashid A; DeJarnette S; Anwer F; Shune L; Raza S; Mahmoudjafari Z; Williams L; Faiman B; McGuirk JP; Sauter CS; Ahmed N; Khouri J; Hashmi H
Blood Cancer J; 2024 May; 14(1):90. PubMed ID: 38821914
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
